<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00361140</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14178</org_study_id>
    <nct_id>NCT00361140</nct_id>
  </id_info>
  <brief_title>Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)</brief_title>
  <official_title>Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-transplant conditioning will include Fludarabine and dose-escalated Busulfan on days -6,
      -5, -4, and -3. Daily treatment doses will be adjusted to achieve target AUCs (area under
      the plasma concentration time curve). Day 0 is the day of hematopoietic progenitor cell
      reinfusion. Supportive care will be based on institutional guidelines. Blood samples will be
      collected for dose modification based on the AUC levels. Dose escalation will proceed to
      determine the maximally tolerated level or AUC to evaluate the potential therapeutic benefit
      of higher doses of busulfan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive anti-seizure prophylaxis beginning on day -7. Pre-transplant
      conditioning will include Fludarabine and dose-escalated Busulfan on days -6, -5, -4, and
      -3. Daily treatment doses will be adjusted to achieve target AUCs (area under the plasma
      concentration time curve). Day 0 is the day of hematopoietic progenitor cell reinfusion.

      Supportive care will be based on institutional guidelines. In an effort to prevent
      hepatotoxicity, ursodiol will be given to patients. During chemotherapy patients will not
      receive concurrent metronidazole, itraconazole, or be given acetaminophen.

      Blood samples will be collected at specific times after Dose 1 and Dose 4 and dose
      modification will be determined or based on the desired AUC levels. Doses 3 and/or 4 will be
      adjusted to achieve an average daily Busulfan AUC over the 4 treatment days.

      Dose escalation will proceed through 3 dose levels to determine the maximally tolerated
      level or AUC to evaluate the potential therapeutic benefit of higher doses of busulfan.

      Graft assessment, processing, and characterization will be done as per institutional
      guidelines. Donor-recipient chimerism (two genetically distinct types of blood cells) will
      be characterized by samples obtained pre-transplant and on days 30+/- 7, 90+/-7 and 360+/-30
      post-transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of subjects dead due to causes unrelated to relapse within the first 100 days post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of subjects with severe VOD / SOS; severity staged according to criteria set forth by McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation:
a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267. Assessed within the first 100 days post transplant</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Leukemia, Lymphocytic</condition>
  <condition>Myeloma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>AUC 6000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan AUC Level 1: 6000 +/- 600 uM-min
Fludarabine 40mg/m2 IV over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AUC 7500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan AUC Level 2: 7500 +/- 750 uM-min
Fludarabine 40mg/m2 IV over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AUC 9000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AUC Level 3: 9000 +/- 900 uM-min
Fludarabine 40mg/m2 IV over 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.
Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.
Subsequent daily doses will be adjusted to achieve target AUCs.</description>
    <arm_group_label>AUC 6000</arm_group_label>
    <arm_group_label>AUC 7500</arm_group_label>
    <arm_group_label>AUC 9000</arm_group_label>
    <other_name>Busulfex(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3</description>
    <arm_group_label>AUC 6000</arm_group_label>
    <arm_group_label>AUC 7500</arm_group_label>
    <arm_group_label>AUC 9000</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Recipient:

          -  HLA A, B, C, DRB1 8/8 or 7/8 matched related or unrelated donor. HLA-DQ mismatches
             are not considered ie they are allowed in addition to these.

          -  Histologically confirmed diagnosis by pathologic review

          -  Diagnosis of any of the following:

               1. AML, ALL, or NHL, in first remission with high risk of relapse, refractory to
                  primary chemotherapy, or after first relapse; acute biphenotypic or
                  undifferentiated leukemia is also included

               2. MDS, with IPSS &gt;1

               3. CML, with GleevecR-refractory or intolerant chronic phase, or beyond chronic
                  phase by morphology or cytogenetics

               4. Myeloproliferative disorders, including Ph-negative CML, myelofibrosis and
                  chronic myelomonocytic leukemia (CMML)

               5. Multiple myeloma, refractory to two or more lines of therapy.

               6. CLL, refractory to fludarabine

               7. Hodgkin's disease, refractory to primary chemotherapy or after first relapse

               8. Karnofsky performance status 70-100%

          -  Organ function:

               1. Pulmonary: DLCO greater than 50%

               2. Cardiac: left ventricular ejection fraction greater than 45%

               3. Renal: creatinine clearance (measured or calculated) equal or greater than 50
                  ml/min

               4. Hepatic: total bilirubin less than or equal to 2mg/dL, (Gilbert and other
                  syndromes with increased indirect bilirubin should be allowed); serum
                  transaminases less than two times the upper limit of normal.

          -  Signed informed consent form in accordance with institutional policies

        Exclusion Criteria - Recipient:

          -  Pregnant or lactating women

          -  HIV or seropositive, confirmed by NAT

          -  Active CNS malignancy

          -  Patients with current uncontrolled bacterial, viral or fungal infection (currently
             taking medication with evidence of progression of clinical symptoms or radiologic
             findings) are ineligible.

          -  Unfavorable psychosocial evaluation or history of poor compliance to prescribed
             medical care

          -  Current use of metronidazole or acetominophen, unless medically necessary; patients
             must discontinue use of these agents at least 7 days prior to the start of BusulfexR
             administration

          -  Prior use of MylotargR (gemtuzumab ozogamicin)

          -  Prior HCT

          -  Prior chest or abdominal irradiation with greater than 1800 cGy

          -  Presence of any of the following comorbid conditions:

               1. History of myocardial infarction or coronary artery disease requiring
                  catheterization or stent placements less than six months prior to enrollment.
                  All subjects with history of myocardial infarction or coronary artery disease
                  must have clearance by a cardiologist to be enrolled

               2. Congestive heart failure (even if symptomatically controlled)

               3. Peripheral vascular disease (including intermittent claudication or history of
                  bypass for arterial insufficiency)

               4. Untreated thoracic or abdominal aneurysm (6cm or more)

               5. History of any cerebrovascular accident including transient ischemic attacks

               6. Dementia

               7. Connective tissue/rheumatologic disorders with active disease

               8. Diabetes uncontrolled by medication (including insulin)

               9. Hemiplegia/paraplegia

              10. History of prior malignancy (excluding nonmelanoma skin or cervical carcinoma
                  after curative resection) less than 5 years from enrollment with the following
                  exception. Cancer treated with curative intent less than 5 years will be
                  reviewed on a case-by-case basis by the Principal Investigator.

              11. History of renal failure requiring renal replacement therapy (e.g.,
                  hemodialysis, peritoneal dialysis, etc)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Field, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janelle Perkins, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org</url>
    <description>Moffiitt Cancer Center Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jul;18(7):1099-107. doi: 10.1016/j.bbmt.2011.12.584. Epub 2011 Dec 23.</citation>
    <PMID>22198540</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>April 24, 2013</lastchanged_date>
  <firstreceived_date>August 3, 2006</firstreceived_date>
  <firstreceived_results_date>January 30, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Chimerism</keyword>
  <keyword>Allogeneic stem cell transplantation (HCT)</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Leukemia Myeloproliferative disorders (MPD)</keyword>
  <keyword>Leukemia, Lymphocytic</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>AUC</keyword>
  <keyword>Hematologic malignancies</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>BMT population recruited from 08/01/2005 through 09/09/2012</recruitment_details>
      <pre_assignment_details>candidates not meeting eligibility criteria excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AUC Level 1</title>
          <description>Busulfan targeted area under the curve, level 1: 6000 +/- 600 uM-min</description>
        </group>
        <group group_id="P2">
          <title>AUC Level 2</title>
          <description>Busulfan targeted area under the curve, level 2: 7500 +/- 750 uM-min</description>
        </group>
        <group group_id="P3">
          <title>AUC Level 3</title>
          <description>Busulfan targeted area under the curve, level 3: 9000 +/- 900 uM-min</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AUC Level 1</title>
          <description>Busulfan targeted area under the curve, level 1: 6000 +/- 600 uM-min</description>
        </group>
        <group group_id="B2">
          <title>AUC Level 2</title>
          <description>Busulfan targeted area under the curve, level 2: 7500 +/- 750 uM-min</description>
        </group>
        <group group_id="B3">
          <title>AUC Level 3</title>
          <description>Busulfan targeted area under the curve, level 3: 9000 +/- 900 uM-min</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)</title>
        <description>The number of subjects with severe VOD / SOS; severity staged according to criteria set forth by McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation:
a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267. Assessed within the first 100 days post transplant</description>
        <time_frame>100 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>AUC 6000</title>
            <description>Busulfan AUC Level 1: 6000 +/- 600 uM-min Fludarabine 40mg/m2 IV over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>AUC 7500</title>
            <description>Busulfan AUC Level 2: 7500 +/- 750 uM-min Fludarabine 40mg/m2 IV over 1 hour</description>
          </group>
          <group group_id="O3">
            <title>AUC 9000</title>
            <description>Busuflan AUC Level 3: 9000 +/- 900 uM-min Fludarabine 40mg/m2 IV over 1 hour</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)</title>
            <description>The number of subjects with severe VOD / SOS; severity staged according to criteria set forth by McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation:
a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267. Assessed within the first 100 days post transplant</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>.007</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Differences in frequencies were were assessed by the chi- squared test.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;.01</p_value>
            <method>Chi-squared</method>
            <param_type>difference in frequencies</param_type>
            <param_value>100</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-relapse Mortality</title>
        <description>The number of subjects dead due to causes unrelated to relapse within the first 100 days post transplant</description>
        <time_frame>100 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>AUC 6000</title>
            <description>Busulfan AUC Level 1: 6000 +/- 600 uM-min Fludarabine 40mg/m2 IV over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>AUC 7500</title>
            <description>Busulfan AUC Level 2: 7500 +/- 750 uM-min Fludarabine 40mg/m2 IV over 1 hour</description>
          </group>
          <group group_id="O3">
            <title>AUC 9000</title>
            <description>Busuflan AUC Level 3: 9000 +/- 900 uM-min Fludarabine 40mg/m2 IV over 1 hour</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Non-relapse Mortality</title>
            <description>The number of subjects dead due to causes unrelated to relapse within the first 100 days post transplant</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sample size will be dependent on dose escalation. Once the MTD is reached, a total of 30 patients will be accrued to that level. If the maximally tolerated AUC is level 1, a total of 30 patients will be treated on this level using tacrolimus and methotrexate as GVHD prophylaxis. This will provide 95% confidence intervals for 100-day non-relapse mortality and non-fatal toxicities with Â½ widths not exceeding 0.18. Hazard ratios were calculated per the method of Gray (reference given)</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>.07</p_value>
            <method>Gray</method>
            <method_desc>Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>6.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>42.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Teresa Field</name_or_title>
      <organization>Moffitt Cancer Center</organization>
      <phone>(813) 745-7202</phone>
      <email>Teresa.Field@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
